David A. Schaer

发表

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

J. Wolchok, A. Houghton, K. Panageas, 2017, Science Signaling.

GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability

J. Wolchok, A. Houghton, T. Merghoub, 2013, Cancer Immunology Research.

Defective Adhesion in Tumor Infiltrating CD8+ T Cells1

A. Frey, D. Schaer, M. Koneru, 2006, The Journal of Immunology.

Defective Adhesion in Tumor Infiltrating and

A. Frey, D. Schaer, M. Koneru, 2006 .

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

P. Iversen, M. Kalos, G. Plowman, 2018, Journal of Immunotherapy for Cancer.

Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

T. Doman, M. Morris, J. Durack, 2020, Clinical Cancer Research.

Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell- proliferative responses via the type I calcitonin gene-related peptide receptor

R. Steinman, J. Carucci, S. Mojsov, 2020 .

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

J. Wolchok, M. Perales, A. Houghton, 2010, PloS one.

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

Srikanth K. Iyer, Valerie A Longo, Erik Herz, 2011, The Journal of clinical investigation.

Abstract A091: Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2016 .

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition

M. Kalos, Xiaohong Xu, S. Castaneda, 2015, Journal of Immunotherapy for Cancer.

Modulation of CTLA-4 and GITR for cancer immunotherapy.

J. Wolchok, A. Yang, F. Avogadri, 2011, Current topics in microbiology and immunology.

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

T. Doman, E. Rasmussen, M. Kalos, 2019, Clinical Cancer Research.

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

M. Kalos, Xiaohong Xu, B. Anderson, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

Paolo A Ascierto, Michael Kalos, P. Ascierto, 2013, Clinical Cancer Research.

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

M. Morris, H. McArthur, C. Klebanoff, 2019, Journal of Clinical Oncology.

A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.

H. Rugo, R. Carvajal, A. Dowlati, 2017 .

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy

David R. Jones, T. Doman, J. Wolchok, 2016, Oncoimmunology.

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody

D. Underwood, J. Wolchok, M. Findeis, 2018, PloS one.

Modulation of GITR for cancer immunotherapy.

J. Wolchok, D. Schaer, Judith T. Murphy, 2012, Current opinion in immunology.

Multimodal microscopy of immune cells and melanoma for longitudinal studies

Ricardo Toledo-Crow, Yongbiao Li, David Entenberg, 2006, SPIE BiOS.

Rational design of anti-GITR-based combination immunotherapy

J. Wolchok, V. Velcheti, M. Hellmann, 2019, Nature Medicine.

First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.

J. Wolchok, T. Merghoub, D. Shepard, 2016 .

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

J. Wolchok, Jedd D Wolchok, David A Schaer, 2014, Journal of Immunotherapy for Cancer.

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy.

J. Wolchok, A. Cohen, D. Schaer, 2010, Current opinion in investigational drugs.

Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

P. Rejto, L. Chen, J. Hardwick, 2021, Molecular Imaging and Biology.

CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis

A. Frey, M. Saio, D. Schaer, 2001, The Journal of Immunology.

Lytic Granule Exocytosis Microtubule-Organizing Center Mobilization Activity Due to Defective Deficient in Perforin-Mediated Cytolytic Tumor-Infiltrating T Cells Are + CD 8

A. Frey, M. Saio, D. Schaer, 2001 .

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety

D. Witcher, Jinsam You, A. Koester, 2018, mAbs.

Hiding the road signs that lead to tumor immunity

J. Wolchok, A. Lesokhin, D. Schaer, 2011, The Journal of experimental medicine.

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope

J. Wolchok, A. Houghton, T. Merghoub, 2011, PloS one.

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

T. Doman, M. Kalos, J. Manro, 2022, PloS one.

Glucocorticoid-Induced TNF Receptor (GITR)

J. Wolchok, A. Cohen, D. Schaer, 2013 .

Rational design of anti-GITR-based combination immunotherapy

J. Wolchok, V. Velcheti, M. Hellmann, 2019, Nature Medicine.

Defective Proximal TCR Signaling Inhibits CD8+ Tumor-Infiltrating Lymphocyte Lytic Function

A. Frey, D. Schaer, M. Koneru, 2005, The Journal of Immunology.

Function Tumor-Infiltrating Lymphocyte Lytic + CD 8 Defective Proximal TCR Signaling Inhibits and

A. Frey, D. Schaer, M. Koneru, 2005 .

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

C. Horak, J. Wolchok, M. Sznol, 2013 .

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

T. Doman, E. Rasmussen, M. Kalos, 2018, Clinical Research (Excluding Clinical Trials).

Abstract CT018: Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial

J. Wolchok, V. Velcheti, M. Callahan, 2017 .

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

J. Haidar, J. M. Sauder, M. Kalos, 2019, Cancer Chemistry.

Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients

J. Wolchok, V. Velcheti, M. Callahan, 2019, Regulating T-cells and Their Response to Cancer.

Calcitonin Gene-Related Peptide Decreases Expression of HLA-DR and CD86 by Human Dendritic Cells and Dampens Dendritic Cell-Driven T Cell-Proliferative Responses Via the Type I Calcitonin Gene-Related Peptide Receptor1

R. Steinman, J. Carucci, S. Mojsov, 2000, The Journal of Immunology.

Peptide Receptor Via the Type I Calcitonin Gene-Related Cell-Driven T Cell-Proliferative Responses Dendritic Cells and Dampens Dendritic Expression of HLA-DR and CD 86 by Human Calcitonin Gene-Related Peptide Decreases

R. Steinman, J. Carucci, S. Mojsov, 2000 .

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

Srikanth K. Iyer, Valerie A Longo, Andrew A. Burns, 2011, The Journal of clinical investigation.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells

L. Swiech, R. Stein, T. Merghoub, 2017 .